scispace - formally typeset
C

Christine M. Stellrecht

Researcher at University of Texas MD Anderson Cancer Center

Publications -  41
Citations -  6074

Christine M. Stellrecht is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Apoptosis & Programmed cell death. The author has an hindex of 18, co-authored 40 publications receiving 5555 citations. Previous affiliations of Christine M. Stellrecht include University of Texas System & University of Texas Health Science Center at Houston.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Mechanisms for T-cell selective cytotoxicity of arabinosylguanine.

TL;DR: It is demonstrated that high ara-GTP accumulation in T cells results in an S phase-dependent apoptosis induced by aarabinosylguanine incorporation into DNA, which may lead to a T cell-specific signal for the induction and liberation of sFasL.
Journal Article

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2459 more
- 01 Jan 2016 - 
Journal ArticleDOI

RNA‐directed agent, cordycepin, induces cell death in multiple myeloma cells

TL;DR: The results suggest that RNA‐directed agents may be a new group of agents for the treatment of MM, and hypothesized that specific genes with short half‐lives may be downregulated, leading to a reduction in protein.
Journal ArticleDOI

MET receptor tyrosine kinase as a therapeutic anticancer target

TL;DR: A review of the MET receptor tyrosine kinase expression and function can be found in this article, where the focus is on targeted therapies that can target MET expression and/or function.